BioMarin Pharmaceutical Inc. (LON:0HNC)
58.01
-1.15 (-1.94%)
At close: Jul 11, 2025
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,040 employees as of December 31, 2024. The number of employees decreased by 361 or -10.61% compared to the previous year.
Employees
3,040
Change (1Y)
-361
Growth (1Y)
-10.61%
Revenue / Employee
751.13K GBP
Profits / Employee
133.38K GBP
Market Cap
8.32B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3,040 | -361 | -10.61% |
Dec 31, 2023 | 3,401 | 319 | 10.35% |
Dec 31, 2022 | 3,082 | 37 | 1.22% |
Dec 31, 2021 | 3,045 | -14 | -0.46% |
Dec 31, 2020 | 3,059 | 58 | 1.93% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Oxford Nanopore Technologies | 1,382 |
BioMarin Pharmaceutical News
- 10 days ago - BioMarin Announces Completion of Acquisition of Inozyme - PRNewsWire
- 17 days ago - BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress - PRNewsWire
- 4 weeks ago - Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs - Benzinga
- 4 weeks ago - Lightning Round: I don't want to buy enterprise software right now, says Jim Cramer - CNBC
- 7 weeks ago - INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY - Business Wire
- 7 weeks ago - BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) - Seeking Alpha
- 2 months ago - BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover - Investor's Business Daily
- 2 months ago - BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal - Seeking Alpha